The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia
- PMID: 22966448
- PMCID: PMC3420697
- DOI: 10.1155/2012/839853
The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia
Abstract
Oxidative stress has been implicated in neurodevelopmental theories of schizophrenia. Antioxidant Peroxysome Proliferator-Activated Receptors α (PPARα) agonist fenofibrate has neuroprotective properties and could reverse early preclinical infringements that could trigger the illness. We have evaluated the neuroprotective interest of fenofibrate in a neurodevelopmental rat model of schizophrenia. The oxidative lesion induced by Kainic Acid (KA) injection at postnatal day (PND) 7 has previously been reported to disrupt Prepulse Inhibition (PPI) at PND56 but not at PND35. In 4 groups of 15 male rats each, KN (KA-PND7 + normal postweaning food), KF (KA-PND7 + fenofibrate 0.2% food), ON (saline-PND7 + normal food), and OF (saline + fenofibrate food), PPI was recorded at PND35 and PND56. Three levels of prepulse were used: 73 dB, 76 dB, and 82 dB for a pulse at 120 dB. Four PPI scores were analyzed: PPI73, PPI76, PPI82, and mean PPI (PPIm). Two-way ANOVAs were used to evaluate the effects of both factors (KA + fenofibrate), and, in case of significant results, intergroup Student's t-tests were performed. We notably found a significant difference (P < 0.05) in PPIm between groups KN and KF at PND56, which supposes that fenofibrate could be worthy of interest for early neuroprotection in schizophrenia.
Figures


Similar articles
-
The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia.CNS Neurosci Ther. 2019 May;25(5):549-561. doi: 10.1111/cns.13087. Epub 2018 Nov 21. CNS Neurosci Ther. 2019. PMID: 30461214 Free PMC article.
-
Delayed onset of prepulse inhibition deficits following kainic acid treatment on postnatal day 7 in rats.Eur J Neurosci. 2004 Nov;20(10):2639-48. doi: 10.1111/j.1460-9568.2004.03731.x. Eur J Neurosci. 2004. PMID: 15548207
-
Altered prepulse inhibition in rats treated prenatally with the antimitotic Ara-C: an animal model for sensorimotor gating deficits in schizophrenia.Psychopharmacology (Berl). 2004 Jul;174(2):177-89. doi: 10.1007/s00213-003-1757-7. Psychopharmacology (Berl). 2004. PMID: 14985933
-
High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway.Nephrol Dial Transplant. 2012 Jun;27(6):2213-25. doi: 10.1093/ndt/gfr613. Epub 2011 Nov 9. Nephrol Dial Transplant. 2012. PMID: 22076434
-
Neurodevelopmental animal models of schizophrenia: effects on prepulse inhibition.Curr Mol Med. 2003 Aug;3(5):459-71. doi: 10.2174/1566524033479627. Curr Mol Med. 2003. PMID: 12942999 Review.
Cited by
-
Current View on PPAR-α and Its Relation to Neurosteroids in Alzheimer's Disease and Other Neuropsychiatric Disorders: Promising Targets in a Therapeutic Strategy.Int J Mol Sci. 2024 Jun 28;25(13):7106. doi: 10.3390/ijms25137106. Int J Mol Sci. 2024. PMID: 39000217 Free PMC article. Review.
-
Abnormal behaviors and developmental disorder of hippocampus in zinc finger protein 521 (ZFP521) mutant mice.PLoS One. 2014 Mar 27;9(3):e92848. doi: 10.1371/journal.pone.0092848. eCollection 2014. PLoS One. 2014. PMID: 24676388 Free PMC article.
-
In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target?Neural Regen Res. 2015 Sep;10(9):1409-12. doi: 10.4103/1673-5374.165313. Neural Regen Res. 2015. PMID: 26604898 Free PMC article. No abstract available.
-
Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish.Front Pharmacol. 2016 Jul 11;7:206. doi: 10.3389/fphar.2016.00206. eCollection 2016. Front Pharmacol. 2016. PMID: 27462272 Free PMC article.
-
PPARα regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving α7 nicotinic acetylcholine receptors.J Neurosci. 2013 Apr 3;33(14):6203-11. doi: 10.1523/JNEUROSCI.4647-12.2013. J Neurosci. 2013. PMID: 23554501 Free PMC article.
References
-
- van Os J, Kapur S. Schizophrenia. The Lancet. 2009;374(9690):635–645. - PubMed
-
- Malaspina D. Schizophrenia: a neurodevelopmental or a neurodegenerative disorder. The Journal of Clinical Psychiatry. 2006;67(8, article e07) - PubMed
-
- Lieberman JA, Jarskog LF, Malaspina D. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. Journal of Clinical Psychiatry. 2006;67(6):983–990. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous